p. 664−664
2008-3874
Vol.16/No.5
p. 665−674
2008-3874
Vol.16/No.5
p. 675−682
2008-3874
Vol.16/No.5
p. 683−688
2008-3874
Vol.16/No.5
p. 689−693
2008-3874
Vol.16/No.5
p. 694−699
2008-3874
Vol.16/No.5
p. 700−704
2008-3874
Vol.16/No.5
99.9 %). Approximately, the whole injected dose has remained in injection site seven days after injection. Conclusion: The complex was proved to be a feasible agent for cavital radiotherapy in oncology and rheumatology]]>
p. 705−709
2008-3874
Vol.16/No.5
p. 710−718
2008-3874
Vol.16/No.5
99%, checked by ITLC). 166Ho-PDTMP complex was stabilized in the final preparation and in the presence of human serum (>90%) up to 72 hr. The biodistribution of 166Ho-PDTMP in wild-type rats demonstrated significant bone uptake was up to 48 hr compared to 166HoCl3. Conclusion: The produced 166Ho-PDTMP properties suggest a possible new bone palliative therapeutic to overcome the metastatic bone pains. ]]>
p. 719−725
2008-3874
Vol.16/No.5
p. 726−730
2008-3874
Vol.16/No.5